11:21 AM EDT, 05/31/2024 (MT Newswires) -- Moderna ( MRNA ) said Friday that the US Food and Drug Administration approved mRESVIA, the company's mRNA respiratory syncytial virus vaccine, that's designed to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.
Price: 146.76, Change: -4.73, Percent Change: -3.12